In conclusion, apatinib combined with chemotherapeutic agent or EGFR‐TKI can improve anti‐tumor activity, which may have the potential of delaying drug resistance and prolonging the survival time of NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.